4157 Stock Overview
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
TaiGen Biopharmaceuticals Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$14.95 |
| 52 Week High | NT$18.75 |
| 52 Week Low | NT$13.85 |
| Beta | 0.78 |
| 1 Month Change | 2.05% |
| 3 Month Change | -2.29% |
| 1 Year Change | -2.29% |
| 3 Year Change | -37.84% |
| 5 Year Change | -16.48% |
| Change since IPO | -76.04% |
Recent News & Updates
Shareholder Returns
| 4157 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -0.7% | -0.5% | 1.8% |
| 1Y | -2.3% | -22.5% | 28.5% |
Return vs Industry: 4157 exceeded the TW Biotechs industry which returned -22.5% over the past year.
Return vs Market: 4157 underperformed the TW Market which returned 28.5% over the past year.
Price Volatility
| 4157 volatility | |
|---|---|
| 4157 Average Weekly Movement | 3.0% |
| Biotechs Industry Average Movement | 4.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 8.2% |
| 10% least volatile stocks in TW Market | 2.0% |
Stable Share Price: 4157 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4157's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Philip Huang | www.taigenbiotech.com.tw |
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenza A, B, and avian influenza H7N9; and Furaprevir, a hepatitis C virus protease inhibitor for the treatment of chronic hepatitis C. The company was founded in 2001 and is based in Taipei City, Taiwan.
TaiGen Biopharmaceuticals Holdings Limited Fundamentals Summary
| 4157 fundamental statistics | |
|---|---|
| Market cap | NT$10.73b |
| Earnings (TTM) | NT$136.73m |
| Revenue (TTM) | NT$123.13m |
78.5x
P/E Ratio87.2x
P/S RatioIs 4157 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4157 income statement (TTM) | |
|---|---|
| Revenue | NT$123.13m |
| Cost of Revenue | NT$11.45m |
| Gross Profit | NT$111.69m |
| Other Expenses | -NT$25.04m |
| Earnings | NT$136.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.19 |
| Gross Margin | 90.70% |
| Net Profit Margin | 111.04% |
| Debt/Equity Ratio | 0% |
How did 4157 perform over the long term?
See historical performance and comparison